Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: A CIBMTR analysis in 3113 AML patients Journal Article
| Authors: | Boyiadzis, M.; Zhang, M. J.; Chen, K.; Abdel-Azim, H.; Abid, M. B.; Aljurf, M.; Bacher, U.; Badar, T.; Badawy, S. M.; Battiwalla, M.; Bejanyan, N.; Bhatt, V. R.; Brown, V. I.; Castillo, P.; Cerny, J.; Copelan, E. A.; Craddock, C.; Dholaria, B.; Perez, M. A. D.; Ebens, C. L.; Gale, R. P.; Ganguly, S.; Gowda, L.; Grunwald, M. R.; Hashmi, S.; Hildebrandt, G. C.; Iqbal, M.; Jamy, O.; Kharfan-Dabaja, M. A.; Khera, N.; Lazarus, H. M.; Lin, R.; Modi, D.; Nathan, S.; Nishihori, T.; Patel, S. S.; Pawarode, A.; Saber, W.; Sharma, A.; Solh, M.; Wagner, J. L.; Wang, T.; Williams, K. M.; Winestone, L. E.; Wirk, B.; Zeidan, A.; Hourigan, C. S.; Litzow, M.; Kebriaei, P.; de Lima, M.; Page, K.; Weisdorf, D. J. |
| Article Title: | Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: A CIBMTR analysis in 3113 AML patients |
| Abstract: | We investigated the impact of the number of induction/consolidation cycles on outcomes of 3113 adult AML patients who received allogeneic hematopoietic cell transplantation (allo-HCT) between 2008 and 2019. Patients received allo-HCT using myeloablative (MAC) or reduced-intensity (RIC) conditioning in first complete remission (CR) or with primary induction failure (PIF). Patients who received MAC allo-HCT in CR after 1 induction cycle had 1.3-fold better overall survival (OS) than 2 cycles to CR and 1.47-fold better than ≥3 cycles. OS after CR in 2 or ≥3 cycles was similar. Relapse risk was 1.65-fold greater in patients receiving ≥3 cycles to achieve CR. After RIC allo-HCT, the number of induction cycles to CR did not affect OS. Compared to CR in 1 cycle, relapse risk was 1.24-1.41-fold greater in patients receiving 2 or ≥3 cycles. For patients receiving only 1 cycle to CR, consolidation therapy prior to MAC allo-HCT was associated with improved OS vs. no consolidation therapy. Detectable MRD at the time of MAC allo-HCT did not impact outcomes while detectable MRD preceding RIC allo-HCT was associated with an increased risk of relapse. For allo-HCT in PIF, OS was significantly worse than allo-HCT in CR after 1–3 cycles. © 2022, The Author(s), under exclusive licence to Springer Nature Limited. |
| Keywords: | adult; retrospective studies; transplantation, homologous; leukemia, myeloid, acute; neoplasm recurrence, local; hematopoietic stem cell transplantation; retrospective study; tumor recurrence; transplantation conditioning; allotransplantation; etiology; acute myeloid leukemia; humans; human |
| Journal Title: | Leukemia |
| Volume: | 37 |
| Issue: | 5 |
| ISSN: | 0887-6924 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2023-05-01 |
| Start Page: | 1006 |
| End Page: | 1017 |
| Language: | English |
| DOI: | 10.1038/s41375-022-01738-3 |
| PUBMED: | 36310182 |
| PROVIDER: | scopus |
| PMCID: | PMC10148918 |
| DOI/URL: | |
| Notes: | Article -- Erratum issued, see DOI: 10.1038/s41375-023-01814-2 --Export Date: 31 May 2023 -- Source: Scopus |
